Tandem Diabetes Care Inc. (TNDM)

43.18
NASDAQ : Health Technology
Prev Close 43.18
Day Low/High 0.00 / 0.00
52 Wk Low/High 2.14 / 52.55
Avg Volume 3.32M
Exchange NASDAQ
Shares Outstanding 57.22M
Market Cap 2.29B
EPS -12.90
P/E Ratio N/A
Div & Yield N.A. (N.A)
TNDM Crosses Above Average Analyst Target

TNDM Crosses Above Average Analyst Target

In recent trading, shares of have crossed above the average analyst 12-month target price of $43.00, changing hands for $43.18/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Tandem Diabetes Care To Webcast Investor & Analyst Day On September 25, 2018

Tandem Diabetes Care To Webcast Investor & Analyst Day On September 25, 2018

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring integration, today announced it will host an Institutional Investor and Analyst Day from 8:30am...

Tandem Diabetes Care To Present At The Baird Global Healthcare Conference

Tandem Diabetes Care To Present At The Baird Global Healthcare Conference

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring integration, today announced that Kim Blickenstaff, president and CEO, will present a company...

Tandem Diabetes Care Announces Commercial Launch Of T:slim X2 Insulin Pump With Basal-IQ Technology In The United States

Tandem Diabetes Care Announces Commercial Launch Of T:slim X2 Insulin Pump With Basal-IQ Technology In The United States

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring (CGM) integration, today announced its launch of the t:slim X2™ Insulin Pump with Basal-IQ™...

Tandem Diabetes Care Announces Full Repayment Of Outstanding CRG Debt

Tandem Diabetes Care Announces Full Repayment Of Outstanding CRG Debt

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring (CGM) integration, today announced that it has fully repaid its term loan made by Capital...

Tandem Diabetes Care Announces Publication Of PROLOG Study Results In Diabetes Care Journal

Tandem Diabetes Care Announces Publication Of PROLOG Study Results In Diabetes Care Journal

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring (CGM) integration, today announced the online publication of results from the PROLOG (PLGS for...

Tandem Diabetes Care Announces Closing Of $115 Million Underwritten Public Offering Of Common Stock

Tandem Diabetes Care Announces Closing Of $115 Million Underwritten Public Offering Of Common Stock

Tandem Diabetes Care ®, Inc. (NASDAQ: TNDM), ("Tandem") a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced the closing of its previously announced underwritten public offering of...

Tandem Diabetes Care Announces Pricing Of $100 Million Public Offering Of Common Stock

Tandem Diabetes Care Announces Pricing Of $100 Million Public Offering Of Common Stock

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM) ("Tandem"), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced the pricing of an underwritten public offering of 3,508,770 shares of...

Tandem Diabetes Care Announces Proposed Underwritten Public Offering Of Common Stock

Tandem Diabetes Care Announces Proposed Underwritten Public Offering Of Common Stock

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM) ("Tandem"), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that it has commenced a proposed underwritten public offering of its...

Tandem Diabetes Care Reports Second Quarter 2018 Financial Results

Tandem Diabetes Care Reports Second Quarter 2018 Financial Results

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pump available in the United States, today reported its financial results for the quarter ended June 30, 2018.

Tandem Diabetes Care Schedules Second Quarter 2018 Earnings Press Release And Conference Call

Tandem Diabetes Care Schedules Second Quarter 2018 Earnings Press Release And Conference Call

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, plans to release its second quarter 2018 results after the financial markets close on Monday, July...

Tandem Diabetes Care Reaches Analyst Target Price

Tandem Diabetes Care Reaches Analyst Target Price

In recent trading, shares of Tandem Diabetes Care Inc have crossed above the average analyst 12-month target price of $22.58, changing hands for $23.14/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Tandem Diabetes Care Announces FDA Approval Of T:slim X2 Insulin Pump With Basal-IQ Technology

Tandem Diabetes Care Announces FDA Approval Of T:slim X2 Insulin Pump With Basal-IQ Technology

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced U.

Okta, Celgene, Altria: 'Mad Money' Lightning Round

Okta, Celgene, Altria: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Okta, Celgene, GasLog Partners, Neutral Tandem, Altria, Axovant Sciences, Lowe's and more.

Tread Carefully: Cramer's 'Mad Money' Recap (Friday 6/15/18)

Tread Carefully: Cramer's 'Mad Money' Recap (Friday 6/15/18)

Jim Cramer says investors need to be cautious, as trade tensions are just one of the things causing markets to whiplash. But he's got your game plan for next week.

Faruqi & Faruqi, LLP Is Investigating Tandem Diabetes Care, Inc. (TNDM) On Behalf Of Its Shareholders

Faruqi & Faruqi, LLP Is Investigating Tandem Diabetes Care, Inc. (TNDM) On Behalf Of Its Shareholders

NEW YORK, June 1, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities law violations at Tandem Diabetes Care, Inc.

Insiders Were Right: TNDM Makes New 52-Week High

In trading on Monday, shares of Tandem Diabetes Care Inc touched a new 52-week high of $13.21/share. That's a 517.29% rise, or $11.07 per share from the 52-week low of $2.14 set back on 02/09/2018.

Insiders Seeing Green With TNDM At New 52-Week High

In trading on Friday, shares of Tandem Diabetes Care Inc touched a new 52-week high of $12.94/share. That's a 504.67% rise, or $10.8 per share from the 52-week low of $2.14 set back on 02/09/2018.

Tandem Diabetes Care To Present At The Bank Of America Merrill Lynch 2018 Healthcare Conference

Tandem Diabetes Care To Present At The Bank Of America Merrill Lynch 2018 Healthcare Conference

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that Kim Blickenstaff, president and CEO, will present a company update at the Bank...

Tandem Diabetes Care To Present At The Deutsche Bank 43rd Annual Health Care Conference

Tandem Diabetes Care To Present At The Deutsche Bank 43rd Annual Health Care Conference

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that Kim Blickenstaff, president and CEO, will present a company update at the...

First Week Of TNDM June 15th Options Trading

Investors in Tandem Diabetes Care Inc saw new options become available this week, for the June 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TNDM options chain for the new June 15th contracts and identified the following put contract of particular interest.

Tandem Diabetes Care Receives CE Mark For T:slim X2 Insulin Pump

Tandem Diabetes Care Receives CE Mark For T:slim X2 Insulin Pump

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps, today announced receipt of CE mark approval for the t:slim X2™ Insulin Pump with Dexcom G5® Mobile continuous glucose...

Tandem Diabetes Care Reports First Quarter 2018 Financial Results

Tandem Diabetes Care Reports First Quarter 2018 Financial Results

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today reported its financial results for the quarter ended March 31, 2018.

Tandem Diabetes Care Announces Agreements For Distribution Of Insulin Pump Products In Australia And New Zealand

Tandem Diabetes Care Announces Agreements For Distribution Of Insulin Pump Products In Australia And New Zealand

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that it has entered into distribution agreements with Australasian Medical &...

Tandem Diabetes Care Announces Upcoming Conference Presentations

Tandem Diabetes Care Announces Upcoming Conference Presentations

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that Kim Blickenstaff, president and CEO, will...

Tandem Diabetes Care Announces 2017 Financial Results

Tandem Diabetes Care Announces 2017 Financial Results

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today reported its financial results for the year and quarter...

Tandem Diabetes Care Applies For Health Canada Medical Device License

Tandem Diabetes Care Applies For Health Canada Medical Device License

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps, today announced its submission of a medical device license application to Health Canada to...

Tandem Diabetes Care And Rubin Medical Announce Agreement For Distribution Of Insulin Pump Products In Scandinavia

Tandem Diabetes Care And Rubin Medical Announce Agreement For Distribution Of Insulin Pump Products In Scandinavia

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that it has entered into a distribution...

Reduced Time In Hypoglycemia Demonstrated In Tandem Diabetes Care's Pivotal Trial For The T:slim X2 Insulin Pump With Predictive Low Glucose Suspend Feature; Data To Be Presented At ATTD 2018 Conference

Reduced Time In Hypoglycemia Demonstrated In Tandem Diabetes Care's Pivotal Trial For The T:slim X2 Insulin Pump With Predictive Low Glucose Suspend Feature; Data To Be Presented At ATTD 2018 Conference

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced positive results from a pivotal study of the...

Tandem Diabetes Care Schedules Fourth Quarter And Full Year 2017 Earnings Press Release And Conference Call

Tandem Diabetes Care Schedules Fourth Quarter And Full Year 2017 Earnings Press Release And Conference Call

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, plans to release its fourth quarter and full year 2017 results...

TheStreet Quant Rating: D- (Sell)